RevenueSep '25Jun '25Mar '25Dec '24Sep '24Jun '24Mar '24Dec '23Sep '23Jun '23Mar '23Dec '22Sep '22Jun '22Mar '22Dec '21Sep '21

Cell Engineering Revenue

29.4

39.1

Biosecurity Product Revenue

—

—

Biosecurity Service Revenue

9.5

10.5

Total Biosecurity Revenue

9.5

10.5

Total Revenue

38.8

49.6

EBITSep '25Jun '25Mar '25Dec '24Sep '24Jun '24Mar '24Dec '23Sep '23Jun '23Mar '23Dec '22Sep '22Jun '22Mar '22Dec '21Sep '21

Cell Engineering Operating Income

-36.7

-9.9

Biosecurity Operating Income

-4.9

-4.8

Corporate Operating Income

—

—

Total EBIT

-90

-65.5

Key Performance IndicatorsSep '25Jun '25Mar '25Dec '24Sep '24Jun '24Mar '24Dec '23Sep '23Jun '23Mar '23Dec '22Sep '22Jun '22Mar '22Dec '21Sep '21

New Programs

—

—

Current Active Programs

—

—

Cumulative Programs

—

—